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A7. HORMONE REPLACEMENT THERAPY AND BREAST CANCER
RISK. THE MILLION WOMEN STUDY1
V. Beral, Oxford, UK
Background: Current use of hormone-replacement therapy (HRT) increases the
incidence of breast cancer. The Million Women Study was set up to investigate
the eﬀects of speciﬁc types of HRT on incident and fatal breast cancer.
Methods: 1084110 United Kingdom (UK) women aged 50–64 years were
recruited into the Million Women Study between 1996 and 2001. They provided
information about their use of HRT and other personal details, and were
followed up for cancer incidence and death.
Findings: Half of the women had used HRT; 9364 incident invasive breast
cancers and 637 breast cancer deaths were registered after an average of 2.6 and
4.1 years of follow-up, respectively. Current users of HRT at recruitment were
more likely than never users to develop breast cancer (adjusted Relative Risk
1.66 [95% Conﬁdence Interval (CI) 1.58–1.75], P < 0.0001) and die from it (1.22
[1.00–1.48], P = 0.05). However, past users of HRT were not at an increased risk
of incident or fatal disease (1.01 [0.94–1.09] and 1.05 [0.82–1.34], respectively).
Incidence was signiﬁcantly increased for current users of preparations containing
oestrogen only (1.30 [1.21–1.40], P < 0.0001), oestrogen-progestagen (2.00 [1.88–
2.12], P < 0.0001), and tibolone (1.45 [1.25–1.68], P < 0.0001), but the
magnitude of the associated risk was substantially greater for oestrogen–
progestagen than for other types of HRT (P < 0.0001). Results varied little
between speciﬁc oestrogens and progestagens or their doses; or between
continuous and sequential regimens. The Relative Risks were signiﬁcantly
increased separately for oral, transdermal, and implanted oestrogen-only
formulations (1.32 [1.21–1.45]; 1.24 [1.11–1.39]; and 1.65 [1.26–2.16], respec-
tively; all P < 0.0001). In current users of each type of HRT, the risk of breast
cancer increased with increasing total duration of use. 10 years of ’ use of HRT is
estimated to result in ﬁve (95% CI 3–7) additional breast cancers per 1000 users
of oestrogen-only preparations and 19 (15–23) additional cancers per 1000 users
of oestrogen–progestagen combinations. Use of HRT by women aged 50–64
years in the UK over the past decade has resulted in an estimated 20 000 extra
breast cancers, 15 000 associated with oestrogen-progestagen; the extra deaths
cannot yet be reliably estimated.
Interpretation: Current use of HRT is associated with an increased risk of
incident and fatal breast cancer; the eﬀect is substantially greater for oestrogen-
progestagen combinations than for other types of HRT.
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Pregnancy protects against breast cancer (BC). Early full-term pregnancy
protects even better. Various hypotheses explain this: terminal diﬀerentiation of
end buds (Russo), auto-immunisation with MUC1 (our group) and a mutual
genetic basis (infertility gene is also susceptibility gene for BC).
Pregnancy after BC is not contra-indicated. This is important as age at ﬁrst
pregnancy goes up, while prognosis for women under 40 years with BC
improves. BC treatment might induce ovarian failure (chemotherapy) or might
impair lactation (radiotherapy). Survival is not negatively inﬂuenced, neither are
the frequency of local recurrences, nor of distant metastases.
Modern women delay child birth and therefore increase their risk of BC
during pregnancy (average frequency 1 in each 5000 pregnancies). On basis of
seven prospective and 41 retrospective studies, the following clinical picture
emerges. Delay in diagnosis is common, as the mammogram is less sensitive
(dense breasts), but safe to the foetus. Abortion is no longer advocated.
Histology should be obtained either by ﬁne-needle aspiration or core biopsy.
Pregnancy-associated tumours are, on average, larger, more often node-
positive and oestrogen receptor (ER)-negative. However, when matched for
age and stage, prognosis is not worse. Mastectomy (without postoperative
radiotherapy) is preferred by many above lumpectomy (with radiation), both
in combination with axillary dissection. Sentinel node procedure with isotopes
is considered contraindicated. Chemotherapy (after ﬁrst semester) and radio-
therapy (after delivery) are safe. Tamoxifen during pregnancy is considered a
risk. In low-stage patients, subsequent pregnancies are not considered to be
contraindicated.
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